Roche AmpliChip Cyp450 for broad diagnostic use:
This article was originally published in Clinica
Executive Summary
Roche has CE-marked for sale in Europe what it claims is the first microarray technology-based test for analysing two genes that can influence drug efficacy and adverse drug reactions. The AmpliChip CYP450 test detects genetic variations in the cytochrome P450 2D6 and 2C19 genes and provides the associated predictive phenotype (poor, intermediate, extensive, or ultra-rapid metaboliser). Results can be used by physicians as an aid for selecting drugs and individualising treatment doses for drugs primarily metabolised by the enzymes encoded by these genes, which play a major role in the metabolism of many widely prescribed drugs. The test incorporates Roche's PCR amplification technology and high-density microarray technology made by Affymetrix.